This second contribution completes the analysis developed in Part 1. Building on the product-centred reasoning adopted by the District Court of The Hague, it examines the limits of that approach in…
In this post, we have mined the Russian patent register for PTE records and processed the data into practical facts and figures.Launch and Major ReformThe modern PTE system of Russia was launched on…
I am particularly pleased to publish this commentary, co-authored with my friend and colleague Marco Stief, whose earlier work on this decision provided the starting point for the present analysis,…
The EU Biotech Act is a legislative initiative aimed at simplifying biotech regulation, boosting innovation and investment, and strengthening Europe’s competitiveness and biotech ecosystem, which we…
BackgroundWe previously set out the background and genesis of the proposed regulatory provisions of the "Proposal for a Directive of the European Parliament and of the Council on the Union Code…
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions (PTE): Otsuka…
Looking at the pharmaceutical law reform package prepared by the European Commission it is clear that, quite sadly, incentivizing inventions and innovation in the pharmaceutical industry no longer…
The Swedish Patent and Market Court (“PMC”) recently issued a judgment on an important aspect of SPC law, namely the correct interpretation of the term ‘product’ under Article 1(b) of the SPC…
Although the equation A + B = C seems self-evident (even for a five years old boy: remember you), the fact remains that it needed clarification by the Court of Justice of the European Union ("CJEU"),…
